Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial.

摘要: In this randomized, double-blind, placebo-controlled clinical trial, we assessed the efficacy and safety of pentoxifylline combination therapy with sertraline in treatment major depressive disorder (MDD). A total 56 patients MDD were assigned into two parallel groups to receive (100 mg/day) plus placebo or (400 mg three times daily) for six weeks. Patients evaluated Hamilton rating scale depression (HAM-D) at baseline weeks 2, 4 6. The group demonstrated greater improvement HAM-D scores from all study time points (P = 0.013, 0.007 0.016 week 6, respectively). Response rate was also significantly higher compared [57.1 vs. 21.4%, P 0.013] endpoint [96.4 57.1%, 0.001]. However, remission rate, response did not show any significant difference between trial groups. Our findings support MDD.